Phase 3 Clinical Trials With Primary Completion Dates in September 2021

This is a list of Phase 3 trials with primary completion dates in September 2021 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ACAD ACADIA Pharmaceuticals Inc. 2021-09-01 Phase 3 NCT04181723 Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDERâ„¢)
AGLE Aeglea BioTherapeutics, Inc. 2021-09-01 Phase 3 NCT03921541 Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency
ANGN Angion Biomedica Corp. 2021-09-01 Phase 3 NCT02474667 Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney
APLIF Appili Therapeutics Inc. 2021-09-01 Phase 3 NCT04600895 The Prevent Severe COVID-19 (PRESECO) Study
BBI Brickell Biotech, Inc. 2021-09-01 Phase 3 NCT03948646 Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302)
FOLD Amicus Therapeutics, Inc. 2021-09-01 Phase 3 NCT03911505 ZIP Study - A Study of the Safety, Pharmacokinetics, Efficacy, Pharmacodynamics, and Immunogenicity of ATB200/AT2221 in Pediatric Subjects Aged 0 to < 18 Years With Pompe Disease
NBIX Neurocrine Biosciences, Inc. 2021-09-01 Phase 3 NCT04102579 Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease
NEPH Nephros, Inc. 2021-09-01 Phase 3 NCT02757872 Effects of Vitamin D and Fish Oil on the Kidney in Hypertensives
PYPD PolyPid Ltd. 2021-09-01 Phase 3 NCT04233424 D-PLEX 311: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection
PYPD PolyPid Ltd. 2021-09-01 Phase 3 NCT03558984 D-PLEX 302: Efficacy and Safety of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery
RDUS Radius Health, Inc. 2021-09-01 Phase 3 NCT04064411 Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis
SCYX SCYNEXIS, Inc. 2021-09-01 Phase 3 NCT04029116 Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)
SCYX SCYNEXIS, Inc. 2021-09-01 Phase 3 NCT03059992 Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
VNDA Vanda Pharmaceuticals Inc. 2021-09-01 Phase 3 NCT04028492 Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis
XFOR X4 Pharmaceuticals, Inc. 2021-09-01 Phase 3 NCT03995108 Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome